Toward a More Rational Policy for Autologous Hematopoietic Stem Cell Mobilization
Open Access
- 1 October 2012
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 18 (10), 1468-1470
- https://doi.org/10.1016/j.bbmt.2012.08.001
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized TrialTransplantation and Cellular Therapy, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposureBone Marrow Transplantation, 2012
- Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple MyelomaTransplantation and Cellular Therapy, 2010
- Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and CyclophosphamideTransplantation and Cellular Therapy, 2010
- Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomideBone Marrow Transplantation, 2010
- Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation, 2010
- Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated PatientTransplantation and Cellular Therapy, 2009